Testing effectiveness (Phase 2)WithdrawnNCT06227897What this trial is testingAumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).Who this might be right forLung Cancer Sun Yat-sen University
Testing effectiveness (Phase 2)UnknownNCT01714908What this trial is testingPhase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21Who this might be right forNon-small Cell Lung Cancer Jinming Yu 100
Testing effectiveness (Phase 2)UnknownNCT01410214What this trial is testingErlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsWho this might be right forNon-small Cell Lung Cancer Stage IIIA Chinese Lung Cancer Surgical Group 80
Large-scale testing (Phase 3)Study completedNCT00874419What this trial is testingErlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 MutationWho this might be right forNon-small Cell Lung Cancer Tongji University 165
Testing effectiveness (Phase 2)Study completedNCT01532089What this trial is testingErlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsWho this might be right forEGFR Exon 19 Deletion MutationEGFR NP_005219.2:p.L858RLung Non-Squamous Non-Small Cell Carcinoma+1 more Academic and Community Cancer Research United 88
Not applicableNot Yet RecruitingNCT05998993What this trial is testingStudy to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)Who this might be right forEGF-R Positive Non-Small Cell Lung CancerNon Small Cell Lung CancerEGFR Exon 19 Deletion+2 more Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 35
Early research (Phase 1)Ended earlyNCT05153408What this trial is testing(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCWho this might be right forLung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more Blueprint Medicines Corporation 20
Large-scale testing (Phase 3)Study completedNCT01024413What this trial is testingPhase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsWho this might be right forThoracic Neoplasms Chinese Society of Lung Cancer 256
Not applicableTemporarily Not AvailableNCT01297101What this trial is testingEvaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant ChemotherapyWho this might be right forNon-small Cell Lung Cancer Shanghai Chest Hospital
Not applicableLooking for participantsNCT06659458What this trial is testingUtilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer PatientsWho this might be right forLung Cancer - Non Small CellEGFR Exon 19 Deletion Mutation Our Lady of the Lake Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT04908956What this trial is testingOsimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)Who this might be right forNSCLC Stage IVEGFR Gene Mutation ETOP IBCSG Partners Foundation 6
Early research (Phase 1)Ended earlyNCT04862780What this trial is testing(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCWho this might be right forLung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more Blueprint Medicines Corporation 177
Testing effectiveness (Phase 2)UnknownNCT01955421What this trial is testingErlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcWho this might be right forAdvanced Stage Non Small Cell Lung Cancer Sun Yat-sen University 224
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290What this trial is testingPhase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsWho this might be right forNon-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more Black Diamond Therapeutics, Inc. 200
Post-approval studies (Phase 4)Ended earlyNCT02695290What this trial is testingAfatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)Who this might be right forCarcinoma, Non-Small-Cell LungErbB Receptors Boehringer Ingelheim 1
Not applicableUnknownNCT06174857What this trial is testingEfficacy of Osimertinib in Patients With Lung CancerWho this might be right forAdvanced Non-Small Cell Lung Cancer Hunan Province Tumor Hospital 100
Not applicableActive Not RecruitingNCT03969823What this trial is testingWhole Genomic Landscape of Advanced EGFR-mutant NSCLCWho this might be right forLocally Advanced or Metastatic NSCLC Seoul National University Hospital 148
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970What this trial is testingHERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyWho this might be right forNonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion Daiichi Sankyo 586
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782What this trial is testingVebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureWho this might be right forNon-Small-Cell Lung Cancer Avistone Biotechnology Co., Ltd. 278
Not applicableUnknownNCT01775943What this trial is testingEfficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLCWho this might be right forLung Neoplasms Ulsan University Hospital 90